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hclamydia
pneumoniae is emerging as a frequent
ause ofrespiratory disease in children as well as
adults. C.pneumoniae infection in children presents a
different set of problems regarding disease presen-
tation and diagnosis compared to adults. Several
studies of the role of C. pneumoniae in lower respira-
tory tract infection in pediatric populations have
found evidence of infection in 0 to over 18%.
1-8 Most
of these studies have relied entirely on serology for
diagnosis. Infection under the age of 5 years has
been rare in Seattle and Scandinavia, whereas in a
study of Filipino children under the age of 5 years
presenting with lower respiratory tract infection,
nearly 10% had either acute or chronic antibody to
C. pneumoniae. In Brooklyn, the proportion of lower
respiratory tract infections associated with C. pneu-
moniae, as determined by culture, increased from
9% in children under the age of 5 to 19% in the
5-16-year-old age category. Recent studies which
have utilized culture have found a poor correlation
between culture and serology, especially in chil-
dren. As part of a multicenter pneumonia treatment
study in children 3-12 years of age, Block et al.
isolated C. pneumoniae from 34 of 260 (13.1%) of
the children enrolled. Serologic evidence of acute
infection was found in 48 (18.5%), but only 8 (23%)
of the culture positive children met the serologic
criteria for acute infection. The serologically posi-
tive, culture negative children usually had stable
high IgG titers, but no detectable IgM antibody.
Most C. pneumoniae infections are probably mild
or asymptomatic. Initial reports emphasized mild
atypical pneumonia clinically resembling that associ-
ated with Mycoplasmapneumoniae. In several subse-
Article
quent studies, however, pneumonia associated with
C. pneumoniae has been clinically indistinguishable
from other pneumonias. Coinfection with other
pathogens, especially M. pneumoniae and Streptococ-
cus pneumoniae can be frequent. In the multicenter
pneumonia treatment study20% ofthe children with
positive C.pneumoniae cultures were coinfected with
M. pneumoniae; they could not be distinguished from
those children who were infected with either organ-
ism alone. The only child in this study who had
pneumonococcal bacteremia also was culture posi-
tive for C.pneumoniae. C.pneumoniae has been associ-
ated with severe illness and even death, although the
role of pre-existing chronic conditions as contribut-
ing factors in many of these patients is difficult to
assess. In some cases, however, C. pneumoniae ap-
pears to be clearly implicated as a serious pathogen
even in the absence of underlying disease. C. pneu-
moniaewas isolated from the respiratory tract and the
pleural fluid of a previously healthy adolescent boy
with severe pneumonia complicated by respiratory
failure and pleural effusions9.
The role ofhost factors remains to be determined.
Although C. pneumoniae has been detected in bron-
choalveolar lavage fluid from 10% of a group of pa-
tients with AIDS and pneumonia, its clinical role in
these patients is uncertain because most were coin-
fected with other well-recognized pathogens such as
Pneumocystis carinii and Mycobacterium tuberculosis.
Gaydos et al., recently identified C. pneumoniae in-
fection by polymerase chain reaction (PCR) in 11%
of a group of immunocompromised adults with
AIDS, malignancies, and otherimmune disorders in-
cluding systemic lupus erythematosus, sarcoidosis,
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and common variable immunodeficiency. We iso-
lated C.pneumoniae from 6 of31 (19%) children with
sickle cell disease presenting with episodes of acute
chest syndrome. C.pneumoniae infection in these pa-
tients appeared to be associated with more severe
hypoxia than infection with M. pneumoniae.
C. pneumoniae appears to act as an inflammatory
trigger for asthma. There are several reports of pa-
tients with culture-documented C.pneumoniae infec-
tion who developed significant bronchospasm, lz,13
One patientwas diagnosed as having asthmatic bron-
chitis and was receiving systemic and topical ste-
roids. 13 She did not improve until her chlamydial in-
fection was treated. Hahn et al., lz reported an
association between serologic evidence of acute C.
pneumoniae infection and wheezing in adults seen for
lower respiratory tract illness. However, they were
able to isolate the organism from only of 365 pa-
tients. As part of a study in children, we isolated C.
pneumoniae from 13 of 118 (11%) children 5-15 years
of age who were initially evaluated for either new
or acute exacerbations of asthma, Treatment of the
infection appeared to result in both clinical improve-
ment and improvement in pulmonary function test
scores in 75% of the infected children. As we ob-
served with the children with community acquired
pneumonia, only 5 of the children with confirmed
infection had detectable IgG antibody to C.pneumon-
iae. One childwho was noncompliantwith his antibi-
otic therapy was culture-positive on five occasions
over a 3-month period. During this time no anti-C.
pneumoniae antibody was ever detected in his sera.
We detected specific anti-C, pneumoniae IgE in
85.7% of the culture-positive asthmatics compared
to9% ofchildren with C.pneumoniaepneumoniawho
were not wheezing.
4 We were also able to detect
anti-C, pneumoniae IgE in sera of 4 patients, 9-41
years of age, with cystic fibrosis and C. pneumoniae
respiratory infection. 15 This suggests that bronchial
reactivity seen with C. pneumoniae infection may be
IgE mediated. The potential of C. pneumoniae to
cause prolonged, persistent infection, often for
months, may produce chronic inflammation and trig-
ger bronchospasm in susceptible individuals. Pre-
liminary studies demonstrate that C. pneumoniae
stimulates production of IL-6 in HEp-2 cells. IL-6
is a precourser for histamine release.
C.pneumoniae has been demonstrated to induce in
vitro ciliostasis in ciliated bronchial epithelial cells.
16
Animal studies also suggest that steroids can reacti-
vate C. pneumoniae lung infection in mice. 17 Hydro-
cortisone has been demonstrated to enhance the
growth of C. pneumoniae in vitro.8 However, hydro-
cortisone did not interfere with the activity ofvarious
antibiotics suggesting that steroid treatment could
be continued if the patients are on appropriate anti-
biotic treatment. Immune-mediated phenomena,
including erythemanodosum and iritis, has also been
described complicating C. pneumoniae infection.9’z
As isolation of C. pneumoniae was difficult and
initially limited, more emphasis was placed on sero-
logic diagnosis. Grayston et al.z originally proposed
a set of criteria for serologic diagnosis of C. pneumon-
iae infection with the MIF test that is used by many
laboratories and clinicians. For acute infection the
patient should have a four-fold rise in IgG titer, a
single IgM titer of 1:16 or greater, or a single IgG
titer of 1:512 or higher. Past or pre-existing infection
is defined as an IgG titer of 1:16 or higher but less
than 1:512. In initial infection, the IgM response
appears about 3 weeks after the onset of illness
and the IgM response appears at 6-8 weeks. In
reinfection, the IgM response may be absent and
the IgG occurs earlier, within 1-2 weeks. Because
of the relatively long period until the development
of a serologic response in primary infection, the
antibody response may be missed if convalescent
sera are obtained too soon, i.e., earlier than 3 weeks
after the onset of illness. Use of paired sera also
only affords a retrospective diagnosis, which is of
little help in terms of deciding how to treat the
patient. The criteria for use of a single serum sample
have not been correlated with the results of culture
and are based mainly on data from adults. The
antibody response in acute infection may take
longer than 3 months to develop. As discussed pre-
viously, acute, culture-documented infection can
also occur without seroconversion, especially in chil-
ren. 1’2’8 Only 28% of the culture-positive children
enrolled in the multicenter pneumonia treatment
study had met the serologic criteria for acute infec-
tion; most had no detectable antibody by the MIF
test even after 3 months of follow-up.
Subsequently, we tested sera from 46 culture pos-
itive children and 42 culture negative children with
pneumonia or asthma by immunoblotting. 22 Over
80% of the culture positive, MIF negative children
had antibodies to a number ofC.pneumoniae proteins
detected by immunoblot. The lack ofdetectable an-
tibody byMIF in these children may be due, in part,
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to low reactivity to the major outer membrane pro-
tein (MOMP); only 23%-26% reacted with the
MOMP. Although the MOMP has been demon-
strated to be immunodominant in the immune re-
sponse to C. trachomatis infection, and antibody to
the MOMP is neutralizing, it does not appear to be
so for C. pneumoniae, z3,z4,z5 Over 75% of the culture
positive children reacted with a 50-52 kDa protein
compared to only 43% of the culture negative chil-
dren. This protein may be a heat shock protein which
is probably genus-specific. However, we could not
determine any specific pattern in terms of reactivity
to various C.pneumoniae proteins in sera from culture
positive and culture negative children, even with
paired sera. Possible serologic cross-reactions of C.
pneumoniaewith C. trachomatis and other bacteriamay
also occur and should be investigated.
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